- Feature Paper
- Review
Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
- Luigi Della Gravara,
- Ciro Battiloro,
- Antonietta Letizia,
- Rosa Cantile,
- Vito D'Agnano,
- Giacomo Sica and
- Danilo Rocco
Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and valid...

